13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001595855
Total reported value
$1.1B
$1.1B
44 檔
30.3%
In Q3 2024, Opaleye Management Inc.'s U.S. equity holdings reached a combined market value of $1.1B, distributed across 44 disclosed stock positions.
In Q3 2024, Opaleye Management Inc. adopted a defensive or profit-taking posture, trimming 18 positions and completely liquidating 13 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | HROW | Harrow Inc | Stock-Other | 29.92% | -3.92% | — | |
| 2 | TGTX | Tg Therapeutics Inc | Stock-Healthcare | 8.89% | +0.32% | — | |
| 3 | OCUL | Ocular Therapeutix Inc | Stock-Other | 7.29% | -0.14% | -5.32% | |
| 4 | ARVN | Arvinas Inc | Stock-Other | 5.16% | — | +126.13% | |
| 5 | CDXS | Codexis Inc | Stock-Other | 4.51% | -0.07% | +153.84% | |
| 6 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 4.37% | -3.42% | -2.91% | |
| 7 | KROS | Keros Therapeutics Inc | Stock-Other | 3.83% | — | +7.56% | |
| 8 | IMNM | Immunome Inc | Stock-Other | 3.02% | — | +12.24% | |
| 9 | LQDA | Liquidia CORP | Stock-Other | 2.83% | +5.97% | +422.51% | |
| 10 | ETON | Eton Pharmaceuticals Inc | Stock-Other | 2.78% | +0.08% | +16.08% | |
| 11 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 2.33% | -0.23% | -9.91% | |
| 12 | CRGX | Cargo Therapeutics Inc | Stock-Other | 1.97% | — | -2.57% | |
| 13 | APLT | Applied Therapeutics Inc | Stock-Other | 1.87% | — | -21.43% | |
| 14 | PCVX | Vaxcyte Inc | Stock-Other | 1.62% | — | — | |
| 15 | NRIX | Nurix Therapeutics Inc | Stock-Other | 1.57% | — | +0.26% | |
| 16 | ✓ | Acelyrin Inc | Stock-Other | 1.56% | — | +19.85% | |
| 17 | TRVI | Trevi Therapeutics Inc | Stock-Other | 1.43% | -0.02% | -2.91% | |
| 18 | ✓ | Biodesix Inc | Stock-Other | 1.16% | — | -5.10% | |
| 19 | DNA | Ginkgo Bioworks Holdings Inc | Stock-Other | 1.11% | — | — | |
| 20 | JSPR | Jasper Therapeutics Inc | Stock-Other | 1.11% | — | -9.82% | |
| 21 | XOMA | Xoma Royalty Corporation | Stock-Other | 1.10% | +0.06% | — | |
| 22 | NUVL | Nuvalent Inc-a | Stock-Other | 1.09% | — | +7.93% | |
| 23 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 0.93% | — | +6.35% | |
| 24 | URGN | UroGen Pharma Ltd. | Stock-Other | 0.86% | +1.41% | -1.92% | |
| 25 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 0.79% | -0.28% | — | |
| 26 | GOSS 5 06-01-27Bond | Gossamer Bio Inc | Bond | 0.70% | — | — | |
| 27 | CYTK | Cytokinetics Inc | Stock-Healthcare | 0.66% | — | -62.07% | |
| 28 | KPTI 3 10-15-25Bond | Karyopharm Therapeutics | Bond | 0.66% | — | — | |
| 29 | GOSS | Gossamer Bio Inc | Stock-Other | 0.62% | — | -6.27% | |
| 30 | ZNTL | Zentalis Pharmaceuticals Inc | Stock-Other | 0.59% | +0.18% | — | |
| 31 | TARA | Protara Therapeutic Inc | Stock-Other | 0.51% | — | -27.04% | |
| 32 | RZLT | Rezolute Inc | Stock-Other | 0.38% | +0.44% | — | |
| 33 | CPRX | Catalyst Pharmaceuticals Inc | Stock-Healthcare | 0.37% | — | -82.42% | |
| 34 | ABCL | Abcellera Biologics Inc | Stock-Other | 0.35% | — | +300.00% | |
| 35 | LYEL | Lyell Immunopharma, Inc. | Stock-Other | 0.32% | — | -16.47% | |
| 36 | ALLKGUSD | Allakos Inc | Stock-Other | 0.26% | — | -13.40% | |
| 37 | RLMD | Relmada Therapeutics Inc | Stock-Other | 0.26% | -0.27% | -20.00% | |
| 38 | PEPG | Pepgen Inc | Stock-Other | 0.26% | — | — | |
| 39 | RVNCEUR | Revance Therapeutics Inc | Stock-Other | 0.24% | — | — | |
| 40 | SYRS | Syros Pharmaceuticals Inc | Stock-Other | 0.23% | — | -24.32% | |
| 41 | ✓ | Stock-Other | 0.15% | — | — | ||
| 42 | RGLS | Regulus Therapeutics Inc | Stock-Other | 0.14% | — | -63.73% | |
| 43 | IBIO | Ibio Inc | Stock-Other | 0.14% | — | — | |
| 44 | ADGM | Adagio Medical Holdings Inc | Stock-Other | 0.05% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | HROW | Harrow Inc | +10.9% | — | Unchanged |
| 2 | CDXS | Codexis Inc | +2.1% | +153.84% | Add |
| 3 | LQDA | Liquidia CORP | +1.9% | +422.51% | Add |
| 4 | ARVN | Arvinas Inc | +1.8% | +126.13% | Add |
| 5 | DNA | Ginkgo Bioworks Holdings Inc | +1.1% | NEW | New buy |
| 6 | ETON | Eton Pharmaceuticals Inc | +1% | +16.08% | Add |
| 7 | ZNTL | Zentalis Pharmaceuticals Inc | +0.6% | NEW | New buy |
| 8 | RZLT | Rezolute Inc | +0.4% | NEW | New buy |
| 9 | PEPG | Pepgen Inc | +0.3% | NEW | New buy |
| 10 | RVNCEUR | Revance Therapeutics Inc | +0.2% | NEW | New buy |
| 11 | ABCL | Abcellera Biologics Inc | +0.2% | +300.00% | Add |
| 12 | PCVX | Vaxcyte Inc | +0.2% | — | Unchanged |
| 13 | APLT | Applied Therapeutics Inc | +0.1% | -21.43% | Trim |
| 14 | NUVL | Nuvalent Inc-a | +0.1% | +7.93% | Add |
| 15 | ADGM | Adagio Medical Holdings Inc | +0.1% | NEW | New buy |
| 16 | KROS | Keros Therapeutics Inc | 0% | +7.56% | Add |
| 17 | ✓ | 0% | — | Unchanged | |
| 18 | IMNM | Immunome Inc | 0% | +12.24% | Add |
| 19 | ✓ | Acelyrin Inc | 0% | +19.85% | Add |
| 20 | PTGX | Protagonist Therapeutics Inc | 0% | — | Unchanged |
| 21 | IBIO | Ibio Inc | 0% | — | Unchanged |
| 22 | EWTX | Edgewise Therapeutics Inc | -0.1% | -9.91% | Trim |
| 23 | ✓ | Reneo Pharmaceuticals Inc | -0.1% | EXIT | Sold out |
| 24 | ✓ | Aligos Therapeutics Inc | -0.1% | EXIT | Sold out |
| 25 | CRGX | Cargo Therapeutics Inc | -0.1% | -2.57% | Trim |
| 26 | RLMD | Relmada Therapeutics Inc | -0.2% | -20.00% | Trim |
| 27 | DSGN | Design Therapeutics Inc | -0.2% | EXIT | Sold out |
| 28 | PMVP | Pmv Pharmaceuticals Inc | -0.2% | EXIT | Sold out |
| 29 | GOSS | Gossamer Bio Inc | -0.2% | -6.27% | Trim |
| 30 | GOSS 5 06-01-27Bond | Gossamer Bio Inc | -0.2% | — | Unchanged |
| 31 | KPTI 3 10-15-25Bond | Karyopharm Therapeutics | -0.2% | — | Unchanged |
| 32 | LYEL | Lyell Immunopharma, Inc. | -0.2% | -16.47% | Trim |
| 33 | ✓ | Biodesix Inc | -0.3% | -5.10% | Trim |
| 34 | XOMA | Xoma Royalty Corporation | -0.3% | — | Unchanged |
| 35 | KPTIEUR | Karyopharm Therapeutics Inc | -0.3% | EXIT | Sold out |
| 36 | TRVI | Trevi Therapeutics Inc | -0.4% | -2.91% | Trim |
| 37 | TGTX | Tg Therapeutics Inc | -0.4% | — | Unchanged |
| 38 | ALLKGUSD | Allakos Inc | -0.4% | -13.40% | Trim |
| 39 | FULC | Fulcrum Therapeutics Inc | -0.4% | EXIT | Sold out |
| 40 | NRIX | Nurix Therapeutics Inc | -0.4% | +0.26% | Add |
| 41 | NAMS | NewAmsterdam Pharma Company N.V. | -0.5% | +6.35% | Add |
| 42 | RYTM | Rhythm Pharmaceuticals Inc | -0.5% | -2.91% | Trim |
| 43 | RGLS | Regulus Therapeutics Inc | -0.5% | -63.73% | Trim |
| 44 | VSTM | Verastem Inc | -0.6% | EXIT | Sold out |
| 45 | VTYXUSD | Ventyx Biosciences Inc | -0.6% | EXIT | Sold out |
| 46 | SVRA | Savara Inc | -0.7% | EXIT | Sold out |
| 47 | TARA | Protara Therapeutic Inc | -0.7% | -27.04% | Trim |
| 48 | LXRX | Lexicon Pharmaceuticals Inc | -0.7% | EXIT | Sold out |
| 49 | URGN | UroGen Pharma Ltd. | -0.7% | -1.92% | Trim |
| 50 | SYRS | Syros Pharmaceuticals Inc | -0.8% | -24.32% | Trim |
According to official SEC Form 13F filings, Opaleye Management Inc. reported a total U.S. public equity portfolio value of $1.1B across 44 disclosed positions in Q3 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including HROW, TGTX, OCUL) accounted for 30.3% of total reported equity market value during Q3 2024.
Top New Position Initiated
DNA
市值: $6.7M
Top Position Liquidated / Trimmed
FDMT
前期市值: $7.3M
During Q3 2024, Opaleye Management Inc.'s top holdings by market value included HROW (29.9%)、TGTX (8.9%)、OCUL (7.3%). The largest single position, HROW, represented 29.9% of total portfolio value.
In Q3 2024, Opaleye Management Inc. made 48 total portfolio adjustments, initiating 6 new buys, adding to 11 positions, trimming 18 holdings, and fully liquidating 13 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.